A neutrophil response linked to tumor control in immunotherapy
Jeremy Gungabeesoon(Harvard University), Mikaël J. Pittet(University of Geneva), Marie Siwicki(Harvard University), Peter D. Koch(Columbia University), Máté Kiss(Vrije Universiteit Brussel), Ruben Bill(University Hospital of Bern), Michael Mazzola(Harvard University), Nicolas A. Gort-Freitas(Harvard University), Krisztián Homicskó(University Hospital of Lausanne), Mehdi Hicham(University of Geneva), Christina Pfirschke(Harvard University), Solange Peters(University Hospital of Lausanne), Allon M. Klein(Harvard University), Ralph Weissleder(Massachusetts General Hospital), Chiara Cianciaruso(University of Geneva), Florent Duval(University of Geneva), Evangelia Bolli(University of Geneva), Christopher Garris(Massachusetts General Hospital), Marius Messemaker(Harvard University)
Cited by 393
Related Papers
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Imaging in the era of molecular oncology
|Nature|2008|2.3k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k